EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
REPORT AND FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020

EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
CONTENTS
Page
RefeRnce and Admlnlstratlve Detai18
Report of the Council of Management
Report of the Auditors
10-13
Consolidated and Association Statement of Financial Activities
14
Consolidated and Association Balance Sheets
15
Consolidated and Association Ststement of Cash Flows
16&17
Statement of Accounting Policies
18-21
Notes to the Financlal Statements
22-30

EUROPEAN RENAL ASSOCIATION -
REFERENCE AND ADMINISTRATIVE DEfAILS
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
status
The following report and financial statements describe the combined affairs of the Association and its
subsidiary o)mpanies consolidated together as a charitable group. A report and financial statements for
the subsidiary company is available separately,
Council of Management
al Five ex-officio members, namely
Prof. Carmine Zoccali (President} Ilerm ended 08.06.2020}
Prof. Christoph Wanner" (Presidenll Iterm stsrted 08.06.20201
Prof, Ivan Rychlik" ISecretary-Treasurerl
Prof. Danilo Fliser, (Renal Science Chair (Chair of Administrative Offices)}
Prof. Denis Fouque. (Editor-in-chief of "Nephrology Dialysis Transplantab'on")
Prof. Ziad Massy. (Chair of the Registry (Clinical Nephrology Governan￿ Chairl}
bl Eight ordinary members, namely..
Prof. Petrijs Johannes Blankestsjn (term ended 08.06.20201
Prof. Annette Noemi Bruchfeld (term ended 08.06.2020)
Prof. Mario Gennaro Cozzolino.
Prof. Ronald Teunis Gansevoort.
Prof. Dimilrios &)umenos'
Dr. Maria Jose Soler Romeo.
Prof. Alexander Rosenkranz. (term started 08.06.20201
Dr. Kathryn Isabelle Stevens"
Prof. Roser Torra. (term started 08.06 20201
Prof. Serhan Z. Tuglular. (term started 08.06.2020}
Prof. Christoph Wanner {term ended 08.06.20201
I'in office at 31 December 2020}
Executlve Manager Monica Fontana
Audltors
PKF Liltlejohn LLP
15 Westferry Circus
Canary Wharf
London E14 4HD
United Kingdom
Registered Charity Number
1060134

EUROPEAN RENAL ASSOCIATION -
REFERENCE AND ADMINISTRATIVE D￿AlLs
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Maln Bankers & Investment Advisors
HSBC UK Bank PIC
69, Pall Mall
Sl James
London SW1Y SEY
United Kingdom
UBS AG
45, Bahnhofstrasse
CH-8098 Zurich
Switzerland
Azimutcapitsl Management
4, Via Cusani
20121 Milano
Italy
Credit Agricole Cariparma
Piazzale Barbieri 291A
43125 Parma
Ilaly
Prlncipal Office
15 Westferry Circus, Canary Wharf
London E14 4HD
United Kingdom
Operatlve Headquarters
Via XXIV Maggio, 38
43123 Parma
Italy
Solicitors
Russell-Cook6
2 Putney Hill
London SW15 6AB
United Kingdom

EUROPEAN RENAL ASSOCIATION-
REPORT OF THE COUNCIL OF MANAGEMENT
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
The members of the Council have pleasure in presenting their repofL together with the audited financial
statements ft)r the year ended 31 $1 De￿mber 2020.
Structure, Govemance and Mana9ement
European Renal Association
European Dialysis and Transplant Association is an unin¢orporaled
association wh￿h was registered with th8 Charity Commissioners on the 14th January 1997 under number
1060134.
The goveming in$trum&nt is the Charity's Constibjtion, which was completely revised and which was finally
approved on June 8, 2020.
The administration of the Association as determined by the Constitution is carried out by..
The Gener81 Assembly
The Council
b}
The President of the AssocAation
dl
The Secretary-Treasurer
The Renal Science Chair (Chair of Adminisliative Offices)
Election of Council Membe
Ordinary members of the Council are elected by the General Assembly. The candidates must be full
members and supported by two otherfull members. The lem ofthe ordinary council members isthree years
bul no more than three ordinary Council members may change each year. Therefore, if more than three
members end their term of office at the same lime, the members necessary lo satisfy this requirement will
remain in office for one more year. The decision as to who will continue will be made by lol or by secret
ballot by the Council members. An ordinary member at the expiry of hislher period of Offi￿ will be ineligible
for re-election as an ordinary member of the Council for a p*riod of three years. There are eight ordinary
council members.
Ex-officio members of the Council are nominated one year in advance by the Council and must then be
elected by the General Assembly. They must be fvll members and also be supported by two other ftjll
members, furthermore the candidates must have at least five years seniority in the Association. There are
five ex-offfcio members..
11 The President of the Association is appointed for a per￿d of three consecutive years and cannot be re-
elected. He or she can only be appointed if he or she was elected as an ordinary council member
21 The Secretary-Treasurer is appointed for a period of three years and may be reelected for a further
period not exceeding three years. except in the special circumstance described below.
3) The Renal Science Chair (Chalr of Administrative Offices) is appointed for three years and may be re-
elected for a fijrther period not extreding three years, except in the special circumstance des¢ribed below.
4) The Edltor in Chief of the official ERA-EDTA Joumal (Nephrology Dialysis Transplantats"on
apF)oinled for three years and may be re*lected for a fvrther period not exceeding three year5.
NDT) is
5) The Chair of the Registy Iclinical Nephrology Governanc2 Chair} is apFJointed for three years and may
be re-elected for a further FerKJd not ex￿edIng three years.
No more than one of the ft)Ilowing ex-Off￿10 members can end their term al the same time.. the Secretary-
Treasurer and the Renal scien￿ Chair (Chair of Administrative Offices}.' un￿sS one of these eX-off￿10
members will ￿ main on the Council as a result of being elected for another ofthe ex-officio posts. Therefore.
if one of these ex-officio members end their term of office at the same lime and is not elected lor another of
the ex-officio posts, the ex-offKio member ￿e￿ssary to satisfy this requirement will remain for one mo
year. The decision as lo who will continue will be taken by the Council upon proposal by the President.

EUROPEAN RENAL ASSOCIATION -
REPORT OF THE COUNCIL OF MANAGEMENT
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Structuro, Governance and Management l¢ontinu¢d
The minimum numter of Counal members is 7. the maximum 13,. there ¢annot be more than people
from the same County.
The Association is represented by its President. or by any other person appointed by the Council.
Members of the Association are Honorary members, Senior members, Full members, A$$ociate members
and Congress members.
The General Assembly is the supreme authority of the Association. The meetings of the General
Assembly can be ordinary or extraordinary.
Inductlon and Training of Councll Members
It is not a requirement that newty elected Council members be trained. All newly elected Council members
received a copy of the Constitution and Rules as well as a presentation regarding the duties and the rule as
trustees with further links of relevant materials all of which they are asked lo read carefully.
Council of Management's Alms. ObJectNgs and Responslbllltles
The Council meets on average three to four b'mes a year, plus there are other informal meetings as required.
The Council is the executive body of the Assoaation and in furtherance of the objects of the Assoaation the
Council may execute powers to..
Raise fvnds
bl
Buy, take on, lease or exchange any property
Subject lo o)nsent, sell, lease or diswse of all or any part of the propety of the Association
Subject lo consent, borrow and charge all or any part of the Property of the Association
Employ and dismiss Staff
c0-0￿rate with other charities
Support any charitable trusts
Incorporate a subsidrary company
Do all such other lawful things to achieve the objects'ves of the ASsocial￿n.
dl
gl
h)
Charity law requires the Trustees to prepare financial statements for eath financial year which give a true
and fair view of the stale of affairs of the Charity and of ils financial activities for that period. In preparing
those financial stslements, the Trustees are required to:
Select suitsble accounting policEs and then apply them consistently
Make judgements and estimates that are reasonable and prudent
Stale whether the F¢)liaes adopted are in accordance with the Statement of Recommended Practice
for Charities, and with applicable accounting standards, subject to any material departures disclosed
and explained in the financial statements
P￿pare the financial stslements on the going COn￿M basis, unless it is inappropriate to assume
that the Charity will continue in business.
b)
dl
The Trustees are responsible for keeping proper accounting records which disclose with reasonable
accuracy al any lime the financial position of the Charity, and enable them to ensure that the financkgl
statements Comp￿ with relevant legislation. They are also responsible for safeguarding the assets of the
Charity, and hence ft)r taking reasonable steps for the prevention and detection of fraud or other
irregularities.

EUROPEAN RENAL ASSOCIATION-
REPORT OF THE COUNCIL OF kfjANAGEMENT
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Struclure, Governance and Management IcontSnued)
Decislon maklng and the relatlon$hlp between offices
Overall il is the General Assembly that is the supreme authority of the Association. The General Assembly
can be ordinary and would be held at the lime and place of the annual congress. or the General Assembly
can be extraordinary, and summoned in special circumstances. The Council however is the executive body
of the Association and acts on ils behalf. The group has offices in various European countries, these offices
are simply executive and not decisional. in fact staff follows the instructions outlined and decided by the
Councll.
Foreign Currencies
The activib'es of the Assoaation are transacted in various foreign currencies, the primary currency being
Euros. The financial statements of the AssocIat￿n are therefore translated into Euros where appropriate.
Subsldiary Trading Companies
The Associatbn has a trading subsidiary company, ERA Eurocongress Limited, a company registered in
England and Wales number 03431245. The company's primary activity is to sell exhibits'on spacE. industry
symposia, advertising and other services to companies mainly in conjunction with congresses arranged by
the Association. ERA Eurocongress Limited received, as a donation. on 4 April 2016 Euromeetings Srl, a
small limited Italian eompany which. on September 4, 2020 wa$ put into liquidation with the aim of closing it
during 2021 at the late$t.
Objeetlves & Activities
The main purpose of the ASs￿latIon is the advancement of medical knowledge for professionals by
promoting scientific and clinical advances in the field of nephrology, dialysis, renal transplantation.
hypertension and related subjects and consequently is for the benefit of the p8tienls and thus the public.
The Association achieves ils objectives by publishing medicaljournals (Nephrology Dialysis Transplantation
and Clinical Kidney Journal, ￿)th published by Oxford Univ. Press). holding annual congresses. producing
epidemiological data for research in the field of interest of the Association through the ERA-EDTA Registry,
organising continuing medical educats'onal courses, supporting fellowships and grants for young
professionals, supporb'ng scientific research ftir important scientific clinical trials that could bring extreme
benefit to nephrology patsents, bul also SUPF)Orting specific working groups and committees that engage
both in research projects as well as in educational courses, producing advise and implementation guidance
as well as position statements for dinical practi￿ thmugh ERBP (European Renal Best Praclicel.
disseminating educational material through its congresses and courses which in 2020 were done all virtually
and co-operating with other scientific organisalions to reach the oth'ectives outlined above.
2020 was a challenging year due to the global Covid-19 pandemic that heavily impacted some of our major
initialive5, among these our fellowship programme but, in particutar, our annual Congress which we were
able lo Iransfom from a traditional live meeting into a fully virtual one in only 11 weeks.
The 2020 Congress was extremely succ8ssfvI both from an income point of view and also a participation
point of view, with over 5.000 delegates attending virtually from all over the world and we were able to keep
the same full scientific programme and key features, including the annual General Assembly at which the
new Constitution was approved for a second time and thLJS became effective.
The pandemic however underlined how hawng within the group a limited company that was in charge of the
organizalion of the annual Congress was a g￿at liability. Al the beginning of September EurThneets'ngs srl.
a limited o)mpany fully owned by ERA-Eurocongress Ltd (owned by ERA-EDTAI was closed and a formal
agreement for the organization of the 2021 Congress was signed with an external professional Congress
organizer IPCO} thus transforming the fixed costs of Euromeelings srl into a variable one and, in summary,
prole¢ling the assets of the Charity.

EUROPEAN RENAL ASSOCIATION -
REPORT OF THE COUNCIL OF MANAGEMENT
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Objectives & Activsties Icontinuedl
This oplimizalion was done also with one of the committees transfomiing its tasks. In September of 2020 il
was decided to change the $¢ope and tasks of ERBP thus no 5onger creating guidelines. which are an
exlrernely costly initiative for a relatively low outcome taking also into consideration that in the fEld of
nephrology there are already other guideline bodies. ERBP is now being restructured to make sure that iys
ex￿lIent group of experts within ils Advisory Board fvlfil their role lo support our members with posilK)n
statements and implementation of already existent guidelines in the field thus delivering excellent advice for
clinical practice for the advancement of nephrology in particular in Europe.
2020 also saw the initsalion of our currently very successful E-seminar programme. having both general hot
topics of interest freely available for all professionals as well as specifi¢ highly educational seminars ft)r our
members that give formal CME accreditation for professional development. this second programme started
in 2021. This programme has also generated an income for the Society thus going into the direction of
allowing the Charity to diversify ils income and thus not to be so dependent on the annual Congress
revenues for its many initiatives.
An important decision taken by Council that went into effect in 2020 was charging author fees for the
Society's Open Access Journal {Clinical Kidney Joumal - CKJI which saw a steady increase in submissions
thus demonstrating how the recently acquired Impact Factor has allowed a higher recognition and reputation
In the nephrology community of our Journal as well a5 becoming a source of income of our Society.
In 2020 two ERA-EDTA supportedlendorsed inilialives received EU funding support.. NEPHROPATH
(Nephrology Pathway} and CONNECT (Cognitive decline in Nephro-Neurology'. European Cooperative
Targell. Furthermore, a project created by our committee NNPC (Nephrology and Public Policy Committee)
PANACEA limProving clinical mANagement of pAlients with CKD using rEal-world dAlal - received an
excellent rating by the EU commission even if. unfortunately, no funding. The long-term final aim of all
these projects 1$ to benefit the patlent outcomes with rogard to survival as well as quality of life.
2020 saw the finalization of grouping under one single website many other external sites of core inib'alNes
of our Society.. Registry, ER8P and all the webcasts of the many talks of our courseslcongresses. We wll
continue our efforts with the aim of making it even more 'swnple anKI easy..
ERA-EDTA fully supports the ERA-EDTA Registry that collects dats from various Dialysis Cenlres in Europe
lo produce epidemiological studies and many excellent papers published in world renown scientific Journals.
It also produc￿1 ext￿melY relevant statistical annual reports that are freely awessible through our website.
ERA-EDTA also supports the ESPNIERA-EDTA Regislrywhich is one oflhe most comprehensive paediatric
nephrology databases worldwide and allows for many important publications.
Creating awareness which is much needed in the field of Nephrology. In 2020, together with ASN (American
Society of Nephrology) and ISN Ilnlemational Soaety of Nephrology) an infographicwas created to illustrate
the huge impact that nephrology ailments have woildwide. in fact. al any given time there are 850.000.000
people who have some kind of kidney diseasel Creating awareness is essential and. again, also for this
reason. ERA-EDTA is part of various Alliances together with other medical Societies..
11 Biomedical Allianee.. ERA-EDTA is actively involved in the CME Icontinuous Medical Education}
Experts Permanent Committee., in the evolvement of Data Protection issues for medical researth in
Europe., in funding opportunities for Research in Europe - BioMedScape', in the Policy Officers Task
Force,. in the Clinical Trial Task Force and in the Journal Publication Committee specifically created
to closely monitor the evolulton of "Plan S.;
2) EKHA- European Kidney Health Alliance. together with the European Dialysis nur5es' association,
the patient's association and the Dutch Kidney Foundation.,
31 KHI IKidney Health Iniliats'vel.
For a fvll and detsiled oulline of the various activities of the AssoclatK)n perfonned in 2020 please go to our
web-site Iwww.era-edta.orgl to view the"2020 Annual Reporf.
We have referred to the guidants contained in the Charity Commissions. general guidan￿ on public beneflt
when reviewing our aims and objectives and in pknning our fvlure activitses.

EUROPEAN RENAL ASSOCIATION -
REPORT OF THE COUNCIL OF MANAGEMENT
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Financial Review
The net movement in group funds as shown by the Ststement of Financial Activities on page 14 shows a
surplu5 Of É1.083,01612019.' É729,1591-
The Group's principal funding sour￿$ are membership fees. congress memberships, congress exhibitions,
various sponsorships mainly linked to the annual congress, unrestricted grants as well as the NDT and CKJ
Journals. 11 is from these incoming ￿SOurceS that the Group is able to achieve and continue to supp)rt its
main obje¢lives
Investment Policy & Perfomiance
The day lo day management of the Association's investrnent fvnds are delegated to professional investment
managers. The Council of Management's Investment policy is to pre*rve the capital to further the
Association's education81 and scientific activities investing a part of il in low I medium risk investments.
The Association's views contsrning investments are that any financial investment made should not cause
a conflict of interest in the ethi[21 or scientific aims of the Association.
Assets are managed by Azimut.
Movements on investments for the year are disclosed at note 8 to the financial statements.
Reserves Policy
The Council of Managemenvs policy on reserves is to accumulate surplus funds sufficient lo sustain all the
activities of the Association for at least a year in the event of some natural or politscal catsslrophe resulting
in the cancellation of the annual congress and therefore the loss of the major source of income for the
Association. The reseNes target Is É6m and al the year end the group held accumulated unrestricted funds
ofÉg,339,67312019'. É8,256,657}.
In accordance ￿th the constitution. the charity holds a 'Reserve Fund, wlhin its reserves which comprises
the total market value of investments held at 31 December 2020 of Q,709,033 {2019.' &.668,2781 together
with cash fvnds of ÉNil. {2019 éNill,' tolalling Q,709,033 {2019'. Q,668,2781 which is below the 'ReseNe
Fund Maximum Amount, ofÉ6,000,000 allowed by the Constitution.
Fundraising Pollcy
We are not currently engaging in any fundraising a¢b"vity.
Risk Management Policy
The Council of Management has examined the principal areas of the Association's actimties and considered
the major risks fa(Ed in each of these areas. In the opinion of the Council of Management the Association
has reviewed systems which under normal cireumstances should allow these risks to be mitigated to an
acceptable level in its day-to4ay operations.
The Council of Management has identified a number of risks and as a ¢onsequence has introduced the
following Risk Management Policy-
Congresses
al Reduction in Attendance
The financial viability of a congress is dependent on the number of registered congress members that
attend. Circumstances out of the control of the Association may arise which significantly reduces the
number of congress members attending the annual congress. To restrict the financial loss which would
ensue, ERA-EDTA and ERA Eurocongress has in place a contract with congress venues and associated
suppliers which allows for 8 reduction in the rental space, temporary staff. and catering, wilhoul incurring
any penalty.

EUROPEAN RENAL ASSOCIATION -
REPORT OF THE COUNCIL OF MANAGEMENT
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Risk Management Policy Icontinuedl
ERA-EDTA has the power lo negob'ale the variable costs in order to Teduce considerably the penalty
fees. Since 2020 ERA-EDTA has invested in virtual IT applications and programmes that allow active
participation by o)ngress attendants also remotely in a virtual matter thus limiting substantially the
problem of having a reduction in attendance.
bl Congrgss Cancellotion
Pandemic situations. acts of terrorism OT political instability may result in the (ancellalion of a congress.
To limit the consequences of this a 'force majeure clause, is included in contracts with all suppliers to
avoid the payment of penalties in case there is a need to cancel the annual congress for such reasons.
As payments are made over a long period of lime and as political instability is difficult to predict. In case
of can￿lIatIOn agreements with the major suppliers have been put in pla￿ to use any eventual down-
payment for a future annual congress Ihus avoiding any kind of penalty fee.
cl Personal Safety
Contracts with congress cenlres and commercial exhibitors who construct exhibition stands or sub-
contract such work to be undertaken musl provide eviden￿ of adequate insurance cover for any
personal injury which may arise as a result of accidents occurring to any congress members, speakers.
or temporary staff. ERA-EDTA has a specific insurance to (x)ver any liability against third parties.
Employees
a) Stafl employed by the Association and Euromeelings Srl are issued wilh appropriate contracts which
meet all legal requirements of the countries where such staff are employed. Staff employed by
Euromeetings Sd were dismissed on 4 Seplemt*r 2020 when Euromeelings was put in liquidation.
b) Obligatory Insuran￿ is included in contracts in all the countries where ERA-EDTA staff are employed.
Additional insurance is available for employees who are required to travel as a consequence of their
employment.
Financial Risks
Investment Managers are inslTUCted not to invest in high-risk funds and additionally are required to
regularly review the investment porttolio and provide a written report lo the Council of the Associab'on.
Records of the Association
al Electronic Files
Files held electronically are copied on a reguL8r basis. such that infomiatB)n is held in at least two
separate centres.
bl Paper Files
Important paper files are held in the administration offices of the Associab'on.

EUROPEAN RENAL ASSOCIATION -
REPORT OF THE COUNCIL OF MANAGEMENT
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Risk Managom•nt Policy (continued)
cl Confldentlallty
Electronic data held by the Association is not disclosed lo third parties without the permtssion of the
Member providing the data.
d) Vlrus and flrowall Prots¢tion
All computers used by the Association arè checked at interyals with the most up to date firewall and
anti-virus sothvare.
COVID-19 Pandemlc
The COVID-19 pandemic present$ a number of key risks to the operations of ERA-EDTA and ils trading
subsidiary ERA-Eurocongress.
The travel bans in pla￿ have meant that Congress 2020 which was due to take place in Milan was switched
to a fvlly virtual Congress. Staff are able to work remotely and records and Systems needed to ensure the
business eontinues are in place. Congress 2021 is planned lo go ahead in Berlin bul in a hybrid version
allowing ERA-EDTA lo switch to a fully virtual congress if needed. The same will be also valid for the
Congress 2022 in Paris and the Congress 2023 in Milan (which was moved from 20201. Whilst there is
expected lo be an impact on subscriptions and memberships, this is not antiCiP81ed to be significant based
on current assessments.
Management and the Trustees are regularty reviewing the financial impact of the COVID-19 pandemic and
taking appropriate ath'ons to miligale the risks arisng, to ensure the business can continue lo grow and
thrive.
Future plans and aellvStle8
One of the most important aims of the AssocIat￿n is to provide excellent education and $cien¢e to
professionals working in the field of fiephroltsgy with the final aim of benefitting the patient, this is even more
important in challenging times such as the ones that we are living in since 2020.
We have learned very usefijl lessons during the year, for example, the Council decided, from now on, to
keep a very substantial virtual component in our annual Congresse$ thu$ making it more inclusive and
sustainable.
In 2020 Council held meetings every tsvo weeks. This inits'alwe, driven by ne￿$Sity, will be kept even in the
future as il allows a much better collaboration among all Counal members for a better understsnding and
thus implementation of all the many inilialives of the Society.
Another key element is the optimEation of the Charity reSoUr￿s, the Council is very attents've lo this
governance aspect of the Association and continuous improvements and measurement are being pul in
place to make sure that the best costleffeetiveness is reached so that more funds can be used for special
new initiatives. like educational webinars supth)rted by our working groups and eommittees, which were
actually implemented in 2021.
Finally, awarenes$, especially among the general population to educate them on kidney health and disease
is key to our fvIU￿ plans and initiatives 50 of whith will be laun¢hed in 2021.
y Order of the Councll
.{Se¢Rtary-T￿¥$urerI

INDEPENDENf AUDrroR'S REPORT TO THE TRUSTEES OF EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Oplnlon
We have audited the financial statements of European Renal Association
European Dialysis and
Transplant Association (the 'parenl charity,) and its subsidiaries {the 'group'l for the year ended 31
De￿mber 2020 which comprise the Consolidated and Parent Charity Statements of Financial Aclivilies.
the Consolidated and Parent Charity Balan￿ Sheets, the Consolidated and Parent Charity Cash Flow
Statements and notes to the financial statements, including significant accounting p)licies. The financial
reporting framework that has been applied in their preparation is applicable law and United Kingdom
Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and
Republic of Ireland (Unitod Kingdom Generally Accepted Accounting PraCts.￿l.
In our oplnlon, the financial stslemenls:
give a true and fair view of the state of the group's and of the parent charity's affairs as at 31
Detsmber 2020 and of the group's incoming resources and application of resources, including its
income and expenditure, for the year then ended,.
have been properly prepared in acwrdance with United Kingdom Generally Accepted Accounting
Practice., and
have been prepared in accordan￿ with the Charities Act 2011.
Ba¥1$ for opinion
We conducted ou¥ audit in accordance with International Standards on Audib'ng IUKI {ISAs IUKII and
applicable law. Our responsibilities under those standards are further described in the Auditorfs
responsibilities for the audit of the financial statements section of our report. We are independent of the
group and parent charity in accordance with the ethical requirements that are relevant lo our audit of the
financial statements in the UK including the FRC'S Ethical Standard, and we have fulfilled ourother ethical
responsibilities in accordance with these requirements. We believe that the audit evidence we have
obtained is sufficient and appropriate lo provide a basis for our opini)n.
Con¢luslon$ relating to golng concern
In auditing the financial statements, we have Concluded that the trustees, use of the going concern basis
of aco)unb'ng in the preparation of the ffinancial statements is appropriate.
Based on the work we have performed, we have not identified any material Un￿rtaIntieS relats'ng to events
or conditions that, indiwdually or ¢olle¢lively, may cast significant doubl on the group's or parent charity's
ability to continue as a going concem for a period of at least twelve months frorn when the financial
ststements are authorised for issue.
Our responsibilities and the re¥)onsibilities of the trustees with respect to going concem are descril￿d in
the relevant sections of this report
Othor information
The other information Comprises the information induded in the Report of the Council of Managemen(
other than the financial statements and our auditor's report thereon. The tru51ees are resFX)n5ible for the
other information contained within the Report ofthe Council of Management. Our opinion on the group and
parent charity financial statements does not Cover the other information and we do not express any fomi
of assurance conclusion Ihereon. Our responsibility is lo read the other information and, in doing so,
consider whether the other information is materially inconsistent with tre ffinancial statements or our
knowledge obtained in the course of the audit, or otherwise
10

INDEPENDEfrif AUDrroR'S REPORT TO THE TRUSTEES OF EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
other Infomiatlon l¢ontinued)
appears lo be materiglly misstated. If we identify such material inconsistencies or apparent material
misstatements, we are required lo determine whether this gives rise to a material misststement in the
financial slalements themselves. If, based on the work we have perfotmed, we conclude that there is a
material misslatemenl of this other information, we are required to reF)Ort that fr4¢1.
We have nothing to report in Ihis regard.
Matter8 on which we are required to report by exception
We have nothing to report in respect of the following matters in relation to which the Charitvès {A¢xounls
and Reports) Regulatsons 2008 require us to report to you if, in our opinion..
the information given in the financial statements ig inconsistent in any material respect with the
trustees, report., or
sufficient accounting records have not been kept., or
the parent charity financ¢al statements are not in agreement with the accounting records.. or
we have not received all the inforMat￿n and explanations we require for our audiL' or
The Counc41 of Management were not entiued lo take advantage of the exemption from preparing
a Strategic ReporL
Responslbllltles of tru$tees
As explained more fvlly in the trustees. responsibilrf(ies sL2tement, the Iruslees are responsible for the
preparation of the group and parent charity financial slalements and for being satisfied that they give a
true and fair view, and for such internal control as the trustees determine is necessary to enable the
preparation of financial slalements that are free from material misstatement, whether due lo fraud or error.
In preparing the group and parent charity financial statements, the trustees are responsible for assessing
the group's and the parent charity's ability to continue as a going COn￿M, disclosing, as applicable.
matters related lo going COn￿M and using the going concern basis of accounting unless the trustees
either intend lo liquidate the group or the parent charity or to cease operations, or have no realistic
alternative but to do so.
Auditor's re8pon8lbllltle8 for the audlt of the flnancial statements
We have been appointed as auditor under section 151 of the Charities Act 2011 and report in accordance
with the Act and the relevant regulations made or having effect thereunder.
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are
ffft from material misstatement. whetherdue to fraud or error, and to issue an auditorfs reportthat includes
our opinion. Reasonable assurance is a high level of assuran￿, bul is not a guarantee that an audit
conducted in accordan￿ with ISAS (UK} will always detect a materk81 misstatement when il exists.
Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate,
they could reasonably be expected to influence the economic decisions of users taken on the basis of
these financial statements.
11

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Auditorf8 responsibililig$ for the audit of the financlal statements Icontinuedl
IrreguSarilies, including fraud, are instances of non-compliance with laws and regulations. We design
procedures in line with our responsibilities, outlined above. to detect material misstatements in respect of
iffegularilies, including fraud. The extent to whi¢h our procedures are capable of detecting irregularities,
including fraud is detailed below..
We obtained an understanding of the group and parent charity and the sector in which they operate
to identify laws and regulations that could reasonably be expected lo have a dirert effect on the
financial slalements. We obtained our understsnding in this regard through discussions with
management, sector research and application of cumulalive audit knowledge and experience of the
sector.
We determined the principal laws and regulations relevant lo the group and parent charity in this
regard to be those arising from the Charlties Act 2011. Charities SORP 2019, Financial Reporting
Standard 102 and UK employment law.
We designed our audit prO￿dureS to ensure the audit team considered whether there were any
indications of non-compliance by the charity wth those laws and regulations. These prO￿dureS
included, but were not limited to enquiries of management. review of minutes and remew of legal
and regulatory correspondence.
We also identified the risks of material misstatement of the financial ststements due to fraud. We
considered, in addition lo the non-rebuttable presumption of a risk of fraud arising from management
override of controls, that there was potential for management bias in the judgements made around
recoverability of debtors. We addressed this through examination of post year end cash received,
review of Corresponden￿ with debtors and discussion of recoverability with management. We also
identified potential for management bias in the allocation of support costs against charitable activity
¢8legories. We addres$ed this through reviewing the method used for reasonableness and re-
performing the calculation to ensure it had been perfoTmed accurately and in line with the ststed
method.
As in all of our audits, we addressed the risk of fraud arising from management override of controls
by perfoiming audit prO￿dureS which included, bul were not limited to.. the lesling of joumals..
reviewing accounting eslimales for eviden￿ of bias,. and evaluating the business rationale of any
significant transactions that are unusual or outside the normal course of business.
Because of the inherent limitstions of an audit, the￿ is a risk thatwe will notdetect all irwularilies, induding
those leading lo a material misststemenl in the financial statements or non-compliance with regulation. This
risk increases the more that Complian￿ with a law or regulation is removed from the events and transaction$
reflected in the financial statements, as we will be less likely to become aware of instances of non-
compliance. The risk is also greater regarding irregularities occurring due to traud rather than error, as fraud
involves intentional concealment, forgery, collusion, omission or misrepresentation.
A furtherdescription of our responsibilities for the audit of the financial statements is located on the Finaneial
Reporting Council's website aL www.frc.or
-ukJaudilorsres
n￿bilItieS. This description foms part of our
auditorfs reporL
12

INDEPENDENT AUDrroR'S REPORT TO THE TRUSTEES OF EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Use of our report
Thls report is made solely to the charity's trustees, as a l)ody, in accordan￿ wth Part 4 of the Charities
(Accounts and Reports} Regulations 2008. Our audit work has been undertaken so that we might slate to
the Gharity's trustees those matters we are reqUI￿d to slate to them in an auditols report and for no other
purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone, other
than the charity and Ihe ¢harity'$ trustees as a body. for our audit worK for this report, or for the opinion$
we have formed.
¢KI LJ¥L IL
15 Westferry Circus
Canary Wharf
London E14 4HD
PKF Llttlelohn LLP
ststutory Auditor
Dale.. 16 July 2021
PKF Littlejohn LLP is ellgible for appointment as auditor of the charity by virtue of its eligibility for
appointment as auditor of a company under section 1212 of the Companies Act 2006
13

EUROPEAN RENAL ASSOCIATION -
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
EUROPEAN DIALYSIS AND TRANSPLANT
YEAR ENDED 31 DECEMBER 2020
ASSOCIATION
Group
Group
Charlty
Charlty
2020
2019
2020
2019
Total
Total
Total
Totsl
unrestricted unrestricted unre8trlcted unrostricted
funds
funds
funds
funds
Income from:
Donations
Donations
Gift aid payments from subsidiary
Note
79.177
104.515
79,177
999,114
104,515
Raising funds
Corporate Spon50r
35,839
35.839
Charitable activities
3.154,928
4.041,935
3,104,657 4,024,521
Other trading activities
Trading activity - Exhibition space, industry
symposia, sponsorship and other ancillary
services
Other trading activty- Euromeetings
1,346,862
158,961
3,523,484
580,609
Investments
Income from investments
Intere51 received
8a
374
374
Other Incom
37,016
{14,3311
10,090
Total
4.776,947
8,272.425
4.193.038 4.165.248
Expenditure on:
Raising funds
PromolDnal activities
other trading activity- Euromeetings
Corporate Sponsor
74,340
7,530
142,724
543,689
74.340
131,513
Charitable actSvltle8
Other
Awards
3,546.333
7.120,104
3,036,695 4,545,574
10,280
10.280
Totsl
3,628,203
7,816,797
3,111,035 4.687,367
Net galns l (expenditure) before net
(losses) I gains on investments
1, 148,744
455.628
1.082,003
1522,1191
Curtency movements on translation
Net gains l (losses) on investments
1106,4831
40,755
60.265
213,266
132,1791
40,755
8a
213,266
Net gains I lexpenditure} and net
movement in fund$
1,083,016
729,159
1.090,579
1308.853)
Reconclliation of funds..
Total funds brought forward
8,256,657
7,527,498
6.683.873 6.992,726
Totsl fund$ Carried forward
9,339.673
8.256,657
7.774,452 6.683,873
All operations are classed as continuing. The notes on pages 18 10 30 fomi part of these accounts.
14

EUROPEAN RENAL ASSOCIATION -
CONSOLIDATED AND ASSOCIATION BALANCE SHEETS
EUROPEAN DIALYSIS AND TRANSPLANT
YEAR ENDED 31 DECEMBER 2020
ASSOCIATION
Group
2020
Group
2019
Charty
2020
Charlty
2019
Notss
Flxed a88ets
Property, plant and equipment
Invesknenls
6,641
23.970
2,709,033 2,668,278
6,641
21,330
2,709,307 2,668,282
3,715,674 2,692,248
2,715,678 2,689,612
Curront Assets
Debtors
Cash al bank and in hand
698.951
1,128,980
10 7,031,788 5,467,544
416,911
283,504
5,630,979 4,145.073
7,730,739 6,596,524 6,047,890 4,428,577
Llabllltle8
Creditors.. Amounts falling due within
one year
11
964,515
916,870
846,891
319.071
Not Current Assgts
6,766,224 5,679,654
5,200,999 4,109,506
Total a88ets1888 curront Ilabllltl08
9,481,898 8,371,902 7,916,677 6,799.118
Creditors.. Amounts falling due after more
one year
11
142,225
115,245
142,225
115,245
Net A88ets
9,339,673 8,256,657
7,774,452 6,683,873
Fund8 of the Charlty
Unrestricted frjnds
9,339,673 8,256,657
7,774,452 6,683,873
Totsl Charlty Funds
9,339,673 8,256,657 7,774,452 6,683,873
The financial statements were aulhorised and approved for issue by the Council of Management and signed
on their behalf
Prof. Iva
Rythlik jsecrelary-Treasu￿rI
j[￿ 25, 2021
The notes on pages 18 to 30 fomi part of these aC￿unts.
15

EUROPEAN RENALASSOCIATION-
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
STATEMENT OF CASH FLOWS
YEAR ENDED 31 DECEMBER 2020
Group
2020
Group
2019
Charty
2020
Charity
2019
Notgs
Nel cash (used inllfrom operating aclivitres
1.565.410
900,093 1,487,072
978,663
Cash flows from Investing activities..
Interest from investments
Dividends from investments
(Purchase} of fixed assets
Proceeds from sale of investrnents
Purchase of investsnents
374
374
(1,1661
15,5911
11,166)
11,6481
11.800,000)
{1,800,0001
Cash provided by investing activities
1,564.224 11,805,217) 1,485,906 {1,801,2741
Change in cash and cash equwalents
in the year
1,564,244
1905.1241 1,485,906
1822,6111
Cash and cash equivalents brought forward
5,467,544 6,372.668 4,145,073 4,967,684
Total cash and cash equivalents carried forward 3 7,031.788
5.467,544 5.630,979 4,145.073
16

EUROPEAN RENALASSOCIATION-
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE STATEMENT OF CASH FLOWS
YEAR ENDED 31 DECEMBER 2020
1 Reconclliation of nèt movements in
funds to net cash flow from operatin9
activitles
Group
2020
Group
2019
Charity
2020
Charity
2019
Net movement in funds for the reporting
period {as per the statement of financial
activities)
1,083,016
729.159 1.090,579 {308.8531
Adjustments for:
Nel Igainsl I Ilossesl on investments
Charges adjustment on investments
Interest re￿1vable
Investment income Ireinvesledl
Deprecialh)n
Loss on disposal of fixed assets
Decrease l {increasel in debtors
Increase I Idecreasel in creditors
146,0911 {213.2661
5,337
660
(374}
{46,091) 1213.2661
5,337
660
13741
15,855
2,638
430,029
74,626
27,934
15,855
22,339
874,847
(518,8671
1133,407) 1,748.840
554.799 {271,057}
Net cash genoratsd from operating
activities
1,565,410
900.093
1 N87,072
978.663
2 Reconciliation of net cash flow to
movement in net funds
Group
2020
Group
2019
CharSty
2020
Charity
2019
Balance al 1 January
Net cash loufflowl l inflow
Exchange gains I Ilossesl on cash
5,467,544 6,372,668
4,145,073 4,967,684
1,670,727
1965,3891 1,518,085 1822.6111
1106.4831
60.265
132,179)
Balance al 31 De￿mber
7.031,788 5.467,544 5.630,979 4.145,073
3 Analysls of ca8h and cash and
cash equlvalents
Group
2020
Group
2019
Charlty
2020
Charity
2019
Cash at bank and in hand
7,031,788 5.467,544
5,630,979 4.145,073
17

EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
1. Ac¢ounting Pollcles
The charity is an unincorporated charity registered in England and Wales and with its principal office
and operatlve he&Jquarters disclosed on page 2. The charitys principal objectives are disclosed on
page 5.
The principal accounting policies, all of which have been applied consistently throughout the year, are
set out below.
a. Ba818 of preparation
The financial statements have been prepared under the historical cost convent￿n with items
recognised at cost or transaction value unless otherwise slated in the relevant accounting policies
telow or the notes to these accounts.
The financial ststements have been prepared in accordan￿ with the Statement of Recnmmended
Practice.. Accounting and Reporting by Charities preparing their accounts in accordance with the
Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 issued in
October 2019 and the Financial Reporting Standard applicable in the United Kingdom and Republi¢
of Ireland IFRS 1021 and the Charities Act 2011 and UK Generally Accepted Practice as it applies
from 1 January 2019.
The financial statements consolidate those of the Charity and its wholly owned non-charitable
subsidiary trading companies. ERA Euro￿ngresS Limited a￿1 Euromeetings Srl up to the date il
was placed into liquidab'on.
The financial statements are prepared in Euros which 1$ the functional currency of the charity and to
the nearest£.
The Charity constitutes a pubfic benefit entity as defined by FRS 102.
b. Going concern
The finanaal slalements are prepared on the going concern basis. ERA-EDTA has ￿nSo11d2ted
reserves of E9.339,673 at 31 De￿Mter 2020 including net current assets of &,766.224 and cash
al bank of f7,031,788.
The Trustees have reviewed the financial position of the charity al 31 December 2020 and
considered their forecasts in relation lo the potential impact of COVID-19 and rA)nsider the charity
is a going concem.
The travel bans in place due lo COVID-19 meant that Congresg 2020 which was due to take pla
in Milan was switched to a fvlly virtual Congress. Staff are able to work remotely and records and
systems needed lo ensure the business continues are in pla￿. Congress 2021 is planned to go
ahead in Berlin but In a hybrid version allowing ERA-EDTA to switch lo a fully virtual congress if
needed. The same will be also valid for the Congress 2022 in Paris and the Congress 2023 in Milan
(which was moved from 20201. Whilst there is expe￿￿ lo be an impact on subscriptions and
memberships. this is not anb'cipated to be signifieanl based on current assessments.
Management and the Trustees are regularly revpwing the finanaal impact of the COVID-19
pandemic and taking appropriate actions to mitlgate the risks arising. to ensure the business can
continue lo grow and thrive.
¢. Fund structure
Unrestricted fvnds are general funds that are available for use at the Councll of Management's
discretion in furtherance of any objeclNes of the charity.
18

EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
1. A¢¢ounting Policies (continued)
d. Income recognitlon
All income is recognised in the period in which the charity is entitled to receipt, the amount can be
measured with reasonable certainty and it is probable that the income will be received, and
specifically as follows..
il Income from trading activities is income receivable by the subsidiary company on selling
exhibition space, industry symposia, sponsorships and other ancillary Se￿1￿$ in connection
with those congresses held by the Assoaalion or with other events organised by the subsidiary
company. Turnover is stated after trade discount9, exclusive of VAT and other sales taxes.
ill Investsnent income includes income from investsnents and bank interest and is recognised in
the year in which il is receivable.
iiil Membership fee income is Tecognised in the year to which fees relate.
iv) Congress proceeds are recognised in the year that the congress was held.
vl Donations from the Association's subsidiary undertaking are recognised on a recelvable basis
and third party grants and donations are recognised in the year In which they are due.
vi) Nephrology Dialysis Transplantation (NDT) and Clinical Kidney Joumal Ickjl. The Association
utilises the seNices of Oxford University P￿sS lo print and to distribute Nephrology Dialysis
Transplantation {NDTI and to publish the online joumal Clinical Kidney Joumal. Each year
Oxford University Press prepares audited financial statements of their activities and the results
and the nel result is either ￿rnItted to the Association or invoiced to the Association. This year
the Journal has made a profit. The net financial effects of these aclivits.es are disdosed as an
incoming resour￿ of the Association and is recognised in the year that the Journal relates.
e. Expenditure recognition
Liabilities are recognised as expenditure as soon as there 1$ a legal or ¢on5tNctive obligation
committing the charity to that expenditure. it is probable that settlement will be required and the
amount of the obligation can be measured reliably. All expendilure is accounted for on an accruals
basis. All expenses including support costs and governan￿ costs are allocated or apportioned to
the applicable expenditure headings.
i) Raising fvnds are those costs attributable lo generating incoming reSoUr￿S for the charity,
other than those costs incurred in undertaking charitable activities or the costs incurred in
undertaking trading activities in fvrtheran￿ of Ihe charity'$ objects.
ill Charitable activities comprise all costs incurred in the pursuit of the charitable objects of the
charity, These costs, where not wholly attributable are apportioned be￿een the categories of
charitable expenditure in addition lo the direct costs. The total cost of each Galegory of
charitable expenditure therefore includes support costs and an apportionment of overheadg.
Grants payable are accrued insofar that the beneficiary has an expectation of receiving a grant
as at the balance sheet dale, but only if such grant is unconditional. Where the charity retain$
its discretion over grants lo be made, and the grants are conditional on the beneficiary satisfying
certain requirements, then such grants are not accrued.
iii) SupFX)rt and govemance costs and allo(2tion
Support costs have been allocated to direct charitable expènditure based on proportion ofdirecl
costs. Governance costs comprise all cos15 involving the public accountability of the charity and
its Complian￿ with regulation and good practice. These costs include costs related lo statutory
audit and legal fees together with an apportionment of overhead and Support costs.
19

EUROPEAN RENAL ASSOCIATION-
EUROPEAN DL4LYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
1. Accounting Policieg Icontinuedl
Property, plant and equlpmenl
Property. plant and equipment costing more than É500 is capitalised and valued at its historlcal cost.
Depreciation is charged over useful economic lives as follows..
Software- 330h on cost perannum.
Office equipment- 330A on cost Fer annum
Electronic equipment_ 330h on cost per annum
Where the recoverable amount of an asset is found to below its net book value, the asset is
written down to its recoverable amount and the loss on impairment 15 charged to the relevant
expenditure category of the statement of financial activities. Where an asset is not primarily used
to generate income, its impairment is assessed by reference to its Servi￿ potential on ils inib'al
acquisition. In the year the charity currently has no tangible fixed assets to which impairment
provisions apply.
g. Fixed asset Investments
Investments are a fomi of basic financial instrument and are initially recognised al their transaction
value and subsequently measured at their fair value as at the balance sheet date using the closing
quoted market PTice. The statement of financial activities includes the nel gains and losses afising
on revaluat¢on and disposals throughout the year.
The Charity does not acquire put options, derivatives or other complex financral instruments. The
main form of financial risk fa￿d by the charity is that of volablily in equity markets and investment
markets due lo wider economic ¢ondilions, the attitude of investors to investment risk, and changes
in sentiment concerning equities and within particular sectors or sub sectors.
h. Reallsed galns and losseg
Realised gains and losses on investments are calculated as the difference beiween sales proceeds
and their market value at the start of the year, or their subsequent cost, and are charged or credited
to the stalen%nt of financial acb"vities in the year of disposal.
Unrealised gains and losses represent the movement in market values during the year and are
credited or charged to the statement of financial activities based on the market value al the year
end.
Foreign currencies
Transaction5 in foreign currencies are translated at an average rate Ca1￿lated for the year.
Monetary assets and liabilities in foreign currencies are translated al the rates of exchange ruling at
the Balance Sheet date. AIS tsther exchange differences are dealt with through the Statement of
Financial Activities.
Taxation
The Association is registered as a charity under the Charities Act 2011 and it is not liable to UK tax
on its income and ehargeable gains, as they fall within the varicws exemptions available to registered
charities.
Following the triennial review of FRS 102 applicable for accounting periods commencing on or after
1 January 2019, there must be a legal obligation in Pla￿ in order for a donation of profit from
subsidiary lo parent lo be re￿gnised in the financial statements. There was no legal obligation in
place at 31 December 2020 and so the donation of the subsidiary company's profit lo ERA-EDTA
has correctly not been recognised within these financial statements. W￿ere the post year end
payment of the profit for the previous financial year is deemed probable, this is taken into account
within the tax computation of the subsKliary company.
20

EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
1. A¢¢ounting Policies Icontinuedl
k. Critical judgemgnts and gstimates
In preparing the financial slalements Trustees make estimates and assumplons which affect
reported results, financial position and disclosure of contingencies. While the assumptions are
believed to be reasonable under current Circumstan￿ actual results could differ from such
estimates. The main areas ofjudgemenl that coijld give rise lo a significant adjustment are..
il Income recognition in respect of the deferral of income
ill Accruals and ¢omrnitrnenls in respect of grants payable
iiil The allocats.on of expenditure be￿een reportab￿ categories
21

EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
2 Incomè- Donatk*ns
Group
2020
Group
2019
Charity
2020
ChaTity
2019
Working Groups
Other
79,177
61,549
42,966
79,177
61,549
42.966
79,177
104,515
79,177
104,515
3 Income- Charltable actlvltles
Group
2020
Group
2019
Charlty
2020
Charity
2019
Congress Proceeds..
Direct - Congress Membership Fees
Ancilliary - Grants receThied
Donations for"Run for Kidneys" pr(4￿t
Membership
Journals and Editork81 Offices
ENP
Grants received
1,516.209
101,200
2,682.390
210,923
1.516.209 2,682,390
101,200
210,923
428,003
1,059,245
358.708
772.500
17,414
428,003
1.059,245
358,708
772.500
50,271
3,154,928
4,041,935
3. 104,657 4.024,521
4 Expendbture- Support Costs
Group
2020
Group
2019
Charlty
2020
Charlty
2019
Officers. Expenses
ERA-EDTA HQ and staff management
Professional Fees
Council Meeting$
Administration Management
Council Regulations & Constitution
Miscellaneous
Bank Charges & Other Commission
Bad Debts
128,200
129,955
462,078
32.147
157,016
7,455
24
48,175
8,140
50.068
425,012
459.402
81,077
50.023
6.455
53,157
71.927
23.173
105,630
101,676
379,645
32,147
119,769
7,455
25,237
85.901
163,431
69,607
39.8D5
6.455
997
22,310
46,618
973.190
1.197.121
792.940
413,743
22

EUROPEAN RENAL ASSOCIATION-
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
4 Charitablo Expenditure- Group
Dlrect cost
Support
cost
2020
Total
2020
Total
2019
2020
Congresses and other trading
Membership
Education
Guidelines
Journals and Editorial Offi￿$
Registry
ENP
Websites, Publicat#)ns & Comms
Fellowships
Research
Working Groups
ComlA
YNP
Relations with Societies and Inslilulions
European Kidney Health Alliance
Participation in Committees
1,502,150
568,129 2,070,279 5.053,058
7,404
12,941
164,745
151,902
888,735
346
354,036
172,137
18,266
177.652
34
4.068
38.225
50,356
26,201
82.345
31,144
113.489
940,828
355.831
1,269,659
47,820
18,086
65.906
2,573,143
973.190
3.546,333 7,120,104
Charltable EXPendi￿re- Charity
Direct cost
Support
cost
2020
Totsl
2020
Total
2019
2020
Congresses and other trading
Membership
Education
Guidelines
Journals and Editorial Offi￿$
Registry
ENP
Websites, Publicab"ons & Comms
Fellowships
Research
Working Groups
ComlA
YNP
Relations with Societies and Inslilulions
European Kidney Health Alliance
Participation in Committees
1,172,762
414,453 1,587,215 2,911.479
6,775
11,843
150,769
139,015
813,341
317
66,404
157,534
16,717
162,582
31
3,723
34,982
46,084
23,979
82,345
29,101
111,446
940,828
332,487
1,273,315
47,819
16,900
64,719
2,243,754
792,941
3,036.695 4,545,574
23

EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
5 Staff Costs
Group
2020
Group
2019
Wages and salaries
Social security costs
661,164
463,425
813,682
533,828
1.124,589 1,347.510
The average number of employees during the year was 12 12019.. 15) with all employee time involved
in providing either support lo the direct operations of the charity or support services lo its governan
and charitable activities.
The number of employees whose total employee benefits exceeded ￿0,000 for the year ended
31 December 2020 and fell within the following band was..
2020
2019
70,001-É80,000
80,001-É90,000
90,001- É100,0110
100,001 - É110,000
150,001 - É160,000
ERA EDTA considers its key rnanagement personnel comprise three from the ex-officio members
(President, Secretary-Treasurer. Renal Science Chair (Chair ofAdminislrative Offices}} detailed on page
1. No key management personnel re￿iVed any remuneration for their services. No Trustees were
remunerated by the charity12019: ÉNill.
During the year ended 31 De￿rnber 2020 sums totalling é7.500 were paid to 10 {2019'. É127,955 paid
to 171 Council members in relation to the reimbursement of travel and Subsisten￿ expenses.
6 Auditors. Remuneration
Group
2020
Group
2019
Fee$ payable to the Company's auditor and its associates for the
audit for the Group's annual financial statements {including
subsidiary companies)
Fees payable to the Company's audltor and its associatgs in
respect of:
Taxation compliance ServI￿S
All other setvices
4,000
3,800
24

EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
7 Tangible Assets - Group
Computer
SOf￿are
Furnlture
Electronic
& Flttlngs Equipment
Totsl
Cost
At 1 January 2020
Additions
Disposals
1,648
24,842
145,642
172.132
1,166
1.166
116,9861 123,459)
16,4731
At31 De￿mber 2020
1,648
18,369
129,822
149.839
Depreclatlon
At1 January 2020
char￿ in year
Disposals
275
549
20,332
4,000
15,9721
127.555
148,612
11.306
15,855
114.847} {20,819)
At 31 De￿mber 2020
824
18,360
124,014
143,198
Net Book Value
31 December 2020
824
5,808
6,641
31 December 2019
1.373
4,510
18.087
23,970
Tangible A88ets- Charfty
Computer
SofI￿are
Furniture
Electronlc
& Fittingg Equipment
Total
Cog1
At 1 January 2020
Additions
Disposals
1,648
18,369
128,657
1,166
148.675
1,166
At 31 December 2020
1.648
18,369
129,823
149,841
Depreclatlon
At 1 January 2020
Charge in year
Disposals
275
549
14,380
4,000
112,709
11,306
127,345
15,855
At 31 December 2020
824
18,360
124,015
143,200
Net Book Value
31 December2020
824
5.808
6,641
31 De￿Mber2O1g
1,373
4,009
15.948
21,330
25

EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
8 Investments - Charity & Group
2020
2019
Group - Listed non-UK investments on recognised
stock exchanges Inole 8a)
2,709.033 2,668.278
Investment in Subsidiaries
Charity 2019
2,709,037 2,668,282
Subsidiary Undertakings
ERA Eurocongress Limited is a company registered in England and Wales under the company number
03431245 and is wholly owned by the Charity. The company prepares financial stslemenls lo
31 De￿mber and has reported the following..
2020
2019
Net assets
Tumover
Expenditure
Profit
1.540,144 1,546,613
1.561,521 3,552,794
11,485,344) 12,528,254)
76,177 1,024,541
Euromeelings Srl is a company registered in Italy. 100Qh of the issued shares of this company were
gifted to Era Eurocongress Lim11ed on 4th April 2016 and from this date the results and net assets of the
company have been consolidated into the group financial stalemenl$ At the date of gift the net as*ts
of Euromeetings Srl amounted to É101,011. The Company, that was put in liquidation at 4 September
2020, prepares financial statements lo 31 December and the following is a summary."
2020
2019
Net assets
Tumover
Expenditure
(Lossl I Profit
91,351
318,847
214,309
940,946
1441,8041 {884,0871
1227.4951
56.859
26

L>
000

EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STA TEMENTS
YEAR ENDED 31 DECEMBER 2020
g Debtor8
Group
2020
Group
2019
Charlty
2020
Charlty
2019
Amounts due from subsKliary undertaking
Trade debtors
Future Congress expenses paid in advance
Membership fees receivab
Other debtors
VAT
16,934
586,054
7,576
86,902
21,485
566,626
403,814
7.576
129.082
21.882
322,534
7,576
86,801
228,364
7,576
47,564
698,951
1,128,980
416.911
283,504
10 Cash at bank and in hand
Group
2020
Group
2019
Charty
2020
Charty
2019
Bank accounts
Petty cash accounts
7,029,345 5,457,441
2,443
10.103
5,628,759 4,142,550
2,220
2.523
7,031,788 5,467,544 5.630,979 4,145,073
11 Creditors: Amounts falling due wlthln one year
Group
2020
Group
2019
Charlty
2020
Charlty
2019
Other creditors
Accruals and deferred income
Amounts due to subsidiary undertaking
123.658
840,857
358,754
558,115
37,550
796,644
12,697
40
306,059
12,697
964,515
916,870
846.891
319.071
Creditors: Amounts falling due after more than one year
Deferred salary
142.225
115,245
142,225
115,245
28

EUROPEAN RENAL ASSOCIATION-
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
Deferred Income
Group
2020
Group
2019
Charty
2020
Charlty
2019
At 1 January
Resources deferred in the year
Amount received from previous year
103,759
116,378
103.759
116,378
77,218
103,759
77.218
103,759
1103,759} 1116,378) (103,7591 1116,378)
At 31 December
77,218
103.759
77.218
103.759
Deferred income mainly relates to membership income received in advan￿ of the following year along
with Congress and grant income received in advance of the following year.
12 Net Assets
2020
Reserve
Fund
2019
ReseThe
Fund
Ggngral
Fund
Goneral
Fund
Total
Total
Fixed Assgts
Property, plant and
8quipmenl
Investments
6,641
6,641
2.709,033 2,709,033
23,970
23.970
2.668,278 2,668,278
6,641 2,709,033 2.715,674
23,970 2.668,278 2,692,248
Net current assets
6.766.224
6,766,224
5,679,654
5,679,654
Creditors due after rr¥)re
than a year
1142,225)
(142,225) {115,2451
1115,2451
Total
6,630,640 2,709,033 9,339,673 5,588,379 2,668,278 8.256.657
In accordance with the Council of Management Report the 'ReseNe Fund. which comprises the total
market value of the investments at the year together with cash fund$ held in those investments tolalled
2,709,03312019: Q,668.2781 which 18 below the'Reserve Fund Maximum Amount of &,000,000.
13 Gifts
The AssocIat￿n receives servres for which no costs are charged. No monetary amounts have been
included within the financial slalemenls as it is difficult to quantify these benefits and in the opinion of
the Members of the Council, these benefits are not material to the accounts.
29

EUROPEAN RENAL ASSOCIATION -
EUROPEAN DIALYSIS AND TRANSPLANT
ASSOCIATION
NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2020
14 Related Parties
As al 31 December 2020 the Association was owed É12.697 12019.. É12,697} from its subsidiary
mpany ERA Eurocongress Limited which indudes ÉO 12019= ÉOI as a gift aid payment. The balance
dIfferen￿S are due to f￿eIgn exchange.
15 Contlngent Liabilities
As noted in the Report of the Council of Management, the Association has indicated its intention to
support research Fyojecls into the future through the payments of grants. These grants are conditional
on the cash flows of the Association and if satisfactory progress of the research projects. Al the year
end the Association had indicated its intention to pay grants tolalling É61,05912019'. É372.1141 in the
lure.
16 Operating Leases
The group had the following future minimum lease payments under non-cancellable operating leases
for each of the reporting periods-.
2020
2019
Payments due
Not later than one year
Later than one year bul not later than five years
16,392
77,800
26,352
59,292
94.192
85,644
30